HAEMONETICS CORP. overview

Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes PR Newswire BOSTON, May 23, 2024 BOSTON , May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the...

Haemonetics Announces Proposed Convertible Senior Notes Offering PR Newswire BOSTON, May 21, 2024 BOSTON , May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended...

Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website PR Newswire BOSTON, May 9, 2024 Financial release accessible online BOSTON , May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer...

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024 PR Newswire BOSTON, April 10, 2024 BOSTON , April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday , May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024 . The call can be...

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge PR Newswire BOSTON, April 4, 2024 BOSTON , April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG ® 6s hemostasis analyzer system Global Hemostasis-HN assay...

Haemonetics Corporation Completes Acquisition of Attune Medical PR Newswire BOSTON, April 1, 2024 BOSTON , April 1, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago -based Attune Medical, the manufacturer of the ensoETM ® proactive esophageal cooling device. EnsoETM is the only FDA-cleared...

Haemonetics Announces Definitive Agreement to Acquire Attune Medical PR Newswire BOSTON, March 5, 2024 BOSTON , March 5, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical products and solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to acquire privately-held Chicago -based Attune Medical, the manufacturer of the ensoETM ® proactive esophageal cooling...

Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day PR Newswire BOSTON, Feb. 21, 2024 BOSTON , Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m. ET . The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations...